Pulmonary Medicine
Medically reviewed by Varun Halani, MD · August 13, 2026
Eosinophilic Asthma
A recognizable asthma phenotype driven by type 2, eosinophilic airway inflammation, identified through blood eosinophil counts and FeNO testing alongside symptom pattern and exacerbation history, and relevant to whether targeted, phenotype-directed treatment may help.
In short
Eosinophilic asthma is a common asthma phenotype, a recognizable pattern rather than a separate disease, driven by type 2 inflammation involving eosinophils, a type of white blood cell. It is identified through a combination of blood eosinophil counts, FeNO testing, symptom pattern, and exacerbation history rather than any single lab value on its own. Recognizing this pattern matters because it can open the door to more targeted, phenotype-directed treatment, including biologic therapy, for patients whose asthma remains poorly controlled on standard inhaled therapy.
Eosinophilic Asthma at a Glance
What It Is
An asthma phenotype driven predominantly by type 2, eosinophilic airway inflammation rather than a separate disease from asthma itself.
How It Is Identified
Blood eosinophil counts and FeNO testing, interpreted alongside symptom pattern, exacerbation history, and current medication use.
Why It Matters
Patients with this pattern often have more frequent or severe flares and may be candidates for more targeted, phenotype-directed treatment.
A Key Caution
A single eosinophil count or FeNO result does not, by itself, establish the diagnosis or a treatment decision.
Key Takeaways
- Eosinophilic asthma is a phenotype, a recognizable pattern of asthma driven by type 2 inflammation, not a condition separate from asthma itself.
- Eosinophils are a type of white blood cell that plays a central role in this inflammatory pattern, which can be assessed through a simple blood test.
- Blood eosinophil counts and FeNO testing are two complementary biomarkers of type 2 inflammation, each with its own strengths and limitations.
- Corticosteroids, inhaled and oral, can lower both blood eosinophil counts and FeNO, so results measured on treatment need to be interpreted with that in mind.
- A pattern of frequent or severe exacerbations is common in eosinophilic asthma and is itself a meaningful piece of the phenotype picture.
- Identifying this phenotype specifically matters because it can open the door to more targeted, biologic treatment options for patients whose asthma remains poorly controlled.
- No single lab result diagnoses eosinophilic asthma on its own; it is interpreted alongside the full clinical picture.
Symptoms
Typical Asthma Symptoms
- Wheezing, chest tightness, and cough
- Shortness of breath that varies over time
- Symptoms that flare with triggers such as infections or exertion
Clues That Suggest an Eosinophilic Pattern
- Asthma that remains poorly controlled despite consistent inhaled therapy
- A history of frequent or severe exacerbations, including any requiring oral steroids
- Elevated eosinophils noted incidentally on routine bloodwork
- Adult-onset asthma without an obvious allergic trigger
- Coexisting nasal polyps or chronic sinus disease
Common Questions When This Pattern Comes Up
My doctor mentioned my eosinophil count. What does that have to do with my asthma?
Eosinophils are a type of white blood cell involved in a specific inflammatory pattern, often called type 2 inflammation, that drives asthma symptoms in many patients. A blood eosinophil count is one way of estimating how active that pattern currently is.
Does an elevated eosinophil count mean I have a more serious form of asthma?
Not automatically. It suggests a particular inflammatory pattern that is associated, on average, with more frequent or severe flares in some patients, but severity is judged from the overall clinical picture, not from one number alone.
I'm already on an inhaled steroid. Could that affect my eosinophil count?
Yes. Inhaled and oral corticosteroids can lower blood eosinophil counts and FeNO, sometimes substantially, which is why a count measured while already on treatment is interpreted with that context in mind rather than at face value.
Why would my doctor want to know my eosinophil count from before I started treatment?
A pre-treatment count, or one measured during a breakthrough exacerbation, often reflects the underlying inflammatory pattern more accurately than a count measured after weeks or months of anti-inflammatory therapy has already suppressed it.
What Drives the Eosinophilic Pattern
Type 2 Immune Signaling
A cascade of immune signals recruits and activates eosinophils in the airway lining, driving inflammation, swelling, and mucus production.
Allergic Sensitization
In some patients, this pattern overlaps with allergic triggers, though eosinophilic asthma can also occur without an identifiable allergic cause.
Adult-Onset Disease
This pattern is disproportionately common in asthma that develops later in life, sometimes without any childhood history of asthma or allergies.
Coexisting Sinus and Nasal Disease
Chronic rhinosinusitis with nasal polyps frequently occurs alongside eosinophilic asthma, reflecting the same underlying inflammatory tendency in a connected part of the airway.
Risk Factors
- Adult-onset asthmaEspecially without a childhood history of wheeze or a clear allergic trigger
- Chronic rhinosinusitis with nasal polypsA frequently coexisting condition that reflects the same type 2 inflammatory tendency
- A history of frequent or severe asthma exacerbations
- Asthma that remains poorly controlled on standard inhaled therapy
- Elevated blood eosinophils noted on prior bloodwork, even if unrelated to asthma at the time
Why the Eosinophilic Pattern Matters
Exacerbation Frequency and Severity
This phenotype is associated, on average, with more frequent or more severe flares, including some requiring oral steroids, urgent care, or emergency treatment.
Oral Corticosteroid Burden
Patients with recurrent exacerbations from this pattern often accumulate repeated oral steroid courses over time, which carries its own long-term risks worth minimizing.
Coexisting Sinus Disease
Nasal polyps and chronic sinus symptoms often track alongside this inflammatory pattern and can affect quality of life independently of asthma control.
Treatment Targetability
Because this pattern is well studied, identifying it specifically opens the door to phenotype-directed treatment options that may not apply to non-eosinophilic asthma.
When Should I Talk to a Pulmonary Specialist?
- Asthma that remains poorly controlled despite consistent, correctly used inhaled therapy
- A pattern of frequent or severe exacerbations, including any requiring oral steroids
- Adult-onset asthma without a clear allergic trigger
- Coexisting nasal polyps or chronic rhinosinusitis alongside asthma
- Uncertainty about which asthma phenotype best fits a patient's presentation
- Consideration of biologic therapy for asthma that remains difficult to control
Overview: A Pattern Within Asthma, Not a Separate Disease
Eosinophilic asthma is one of the most recognizable, best-studied phenotypes of asthma, a distinct pattern rather than a separate condition. Every patient with it still has asthma, with the same variable, often reversible airway narrowing. What sets the phenotype apart is the specific type of inflammation driving it.
Eosinophils are a type of white blood cell that is part of the body’s normal immune response, typically defending against parasites and driving allergic reactions. In many people with asthma, eosinophils are recruited into the airway lining as part of a broader immune signaling pattern called type 2 inflammation. When that pattern is prominent enough on testing, and fits the clinical picture, the asthma is described as eosinophilic.
Type 2 Inflammation: The Broader Pathway
The Type 2, Eosinophilic Pathway
Type 2 inflammation is a cluster of immune signals that recruit and activate eosinophils in the airway lining, contribute to swelling, and increase mucus production. It is the most extensively studied inflammatory pathway in asthma, which is part of why current diagnostic testing and biologic therapies center on it. Eosinophilic asthma is essentially the clinical expression of a strongly type 2, eosinophil-predominant pattern.
Non-Type-2 (Type 2-Low) Asthma
Not every case of asthma follows this pathway. A smaller share of patients have asthma driven by inflammation that is not primarily type 2 or eosinophilic, sometimes described as non-type-2 or “type 2-low” asthma. This distinction matters because it influences which treatment approaches, particularly biologic therapies, are likely to help a given patient.
How Eosinophilic Asthma Is Identified
No single test defines eosinophilic asthma. Instead, a physician builds a picture using several complementary pieces of information, weighed together rather than in isolation, roughly in the sequence below.
The Identification Pathway
- 01Symptom PatternAsthma that is poorly controlled, adult-onset, or marked by frequent exacerbations raises suspicion for this phenotype.
- 02Blood Eosinophil CountA standard blood test estimates how active type 2 inflammation currently is.
- 03FeNO TestingA breath test offers a second, complementary window into airway inflammation.
- 04Exacerbation History ReviewHow often, and how severely, asthma has flared adds further weight to the picture.
- 05Biologic Eligibility DiscussionIf the pattern fits and control remains poor, phenotype-directed treatment is considered.
Blood Eosinophil Counts
A standard blood test measures eosinophils circulating in the bloodstream, reported as cells per microliter. Higher counts support a type 2, eosinophilic pattern, and thresholds of roughly 150 to 300 cells per microliter, or higher, are commonly referenced. The number that matters depends on the clinical question, whether that’s diagnosis, exacerbation risk, or biologic eligibility.
There is no single universal cutoff applied identically in every situation. A count is always interpreted by a physician within that broader context, not read as a fixed pass-or-fail number.
FeNO Testing
FeNO testing is a simple breath test that measures nitric oxide in exhaled air, offering a second, complementary window into type 2 airway inflammation. Neither FeNO nor a blood eosinophil count is a stand-alone diagnostic test for eosinophilic asthma; each can be informative in situations where the other is less clear, and both are most useful considered together, alongside the rest of the clinical picture.
Blood Eosinophils vs. FeNO
| Dimension | Blood Eosinophil Count | FeNO |
|---|---|---|
| What It Measures | A specific white blood cell type in the bloodstream | Nitric oxide in exhaled breath |
| Reflects | Systemic eosinophil activity | Local airway inflammation |
| Affected By Corticosteroids | Yes, can drop substantially on treatment | Yes, can drop substantially on treatment |
| Stand-Alone Diagnostic? | No | No |
| Most Useful When | Considered together with FeNO and the full clinical picture | Considered together with the eosinophil count and the full clinical picture |
Exacerbation History
How often, and how severely, a patient’s asthma has flared is itself part of the eosinophilic phenotype picture, not simply a separate symptom to track, and this pattern is associated, on average, with more frequent or severe exacerbations than some other asthma patterns. A detailed history of past flares, including how they were treated, often adds as much diagnostic value as a single lab result.
Why Corticosteroids Complicate Biomarker Interpretation
Inhaled and oral corticosteroids are the foundation of standard asthma treatment, and they work partly by reducing the very type 2 inflammation these biomarkers measure. Both blood eosinophil counts and FeNO can drop, sometimes substantially, once a patient has been on corticosteroid therapy for even a short time, so a count measured after weeks of inhaled steroid use may understate the true underlying inflammatory tendency.
Because of this, physicians often place particular weight on a pre-treatment eosinophil count, if one is available, or on a count obtained during a breakthrough exacerbation before steroids are started or stepped up. Either can offer a more accurate picture of the underlying pattern than a value drawn from a patient who is already stably treated. This is a reasonable thing for patients to ask about directly if phenotype testing is being discussed.
Why Identifying This Phenotype Specifically Matters
Recognizing an eosinophilic pattern is not simply an academic exercise. Because type 2, eosinophilic inflammation is the most extensively studied inflammatory pathway in asthma, identifying it specifically opens the door to phenotype-directed treatment, including biologic medications that target this pathway directly, for patients whose asthma remains poorly controlled despite appropriately used standard inhaled therapy.
These treatment options are generally not appropriate for asthma that does not follow this pattern. That is part of why accurate phenotype identification, rather than treating all asthma as one uniform disease, has become a meaningful part of current care for harder-to-control asthma.
At the same time, standard inhaled anti-inflammatory therapy remains the foundation of treatment regardless of phenotype, considered first before any phenotype-directed option. Biologic therapy for asthma involves several distinct medications and eligibility considerations detailed enough to warrant its own dedicated discussion, not summarized here.
A Single Lab Value Does Not Make the Diagnosis
It’s worth stating plainly: one blood eosinophil count or one FeNO result, taken on its own, does not establish a diagnosis of eosinophilic asthma, and it does not, by itself, determine a treatment decision such as starting biologic therapy. Both biomarkers can be affected by current medication use, timing, and even factors unrelated to asthma.
A physician interprets any single result alongside symptom pattern, exacerbation history, response to treatment so far, and the broader clinical picture, sometimes repeating testing at a different time or under different treatment circumstances before drawing a conclusion.
Living With Eosinophilic Asthma
For most patients, an eosinophilic asthma pattern is identified during evaluation for asthma that isn’t responding as expected to standard inhaled treatment, or during a broader phenotype assessment after a pattern of frequent exacerbations. Confirming this phenotype does not change the day-to-day fundamentals of asthma self-management, but it does inform the conversation about whether additional, more targeted treatment is worth pursuing.
VitalAir Sleep & Lung Center evaluates asthma phenotype, including blood eosinophil counts, FeNO testing, and exacerbation history, for patients across Frisco and the broader North Dallas–Fort Worth area, and discusses phenotype-directed treatment for asthma that remains difficult to control. This clinical information applies wherever you’re reading it from; what differs locally is simply where that evaluation and follow-up care happens.
Patient Questions
What is eosinophilic asthma, exactly?
It is a common asthma phenotype, a recognizable pattern of the disease, driven predominantly by type 2 inflammation involving eosinophils, a type of white blood cell. It is not a separate disease from asthma; it describes a particular inflammatory pattern that a given patient's asthma follows.
What are eosinophils?
Eosinophils are a type of white blood cell that is part of the immune system's response to certain triggers, including parasites and allergens. In asthma, eosinophils recruited into the airway lining contribute to inflammation, swelling, and mucus production as part of what is often called type 2 inflammation.
What is "type 2 inflammation"?
It is a broad immune signaling pattern that, among other effects, recruits and activates eosinophils. Type 2 inflammation is the most extensively studied inflammatory pathway in asthma and underlies the eosinophilic phenotype, though a smaller share of asthma follows a different, non-type-2 inflammatory pattern instead.
How is eosinophilic asthma identified?
Through a combination of a blood eosinophil count, FeNO testing, symptom pattern, and exacerbation history. No single test defines the phenotype on its own; a physician interprets these pieces together, alongside how the asthma has responded to treatment so far.
Is there a specific eosinophil number that defines eosinophilic asthma?
There isn't one universal cutoff used in every context. Clinically, blood eosinophil counts in a range of roughly 150 to 300 cells per microliter, or higher, are often used as supporting evidence of this pattern, with the specific threshold depending on the clinical question being asked, such as diagnosis versus biologic treatment eligibility. This is a conceptual range interpreted by a physician, not a fixed rule applied identically to every patient.
How does FeNO testing relate to blood eosinophils in this evaluation?
Both are biomarkers of type 2 inflammation, but they measure different things. FeNO measures nitric oxide in exhaled breath, while a blood eosinophil count measures a specific white blood cell type in the bloodstream. They are often considered together, since each can be informative in slightly different situations and neither is a perfect stand-alone marker.
Can inhaled or oral steroids affect my eosinophil count or FeNO result?
Yes, meaningfully. Both inhaled and oral corticosteroids can lower blood eosinophil counts and FeNO, sometimes substantially, which means a result measured after weeks of treatment may understate the underlying inflammatory pattern. A pre-treatment count, or one obtained during a breakthrough exacerbation before steroids are started or increased, is often more informative.
Why do people with eosinophilic asthma often have more exacerbations?
This inflammatory pattern is associated, on average, with a higher likelihood of frequent or severe flares compared with some other asthma patterns, though individual experience varies. This exacerbation history is itself considered part of the phenotype picture, not just a separate symptom to note.
Why does identifying this specific phenotype matter for treatment?
Because eosinophilic, type 2 inflammation is well studied, identifying it specifically opens the door to phenotype-directed treatment options, including biologic therapy, that target this inflammatory pathway directly. These options are generally not appropriate for asthma that does not follow this pattern, which is part of why accurate phenotype identification matters.
Does a single elevated eosinophil count mean I need biologic therapy?
No. A single lab value, whether a blood eosinophil count or a FeNO result, does not by itself establish a diagnosis of eosinophilic asthma or a decision to start biologic therapy. These results are interpreted alongside symptom pattern, exacerbation history, current medication use, and the full clinical picture by a physician.
Sources
Guidelines and Professional Societies
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2026 Update.View source
- Global Initiative for Asthma (GINA). GINA Severe Asthma Guide, 2026.View source
- Dweik RA, Boggs PB, Erzurum SC, et al. An Official ATS Clinical Practice Guideline, Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. American Journal of Respiratory and Critical Care Medicine, 2011.View source
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. European Respiratory Journal, 2014.View source